SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-020460
Filing Date
2024-05-17
Accepted
2024-05-17 16:51:55
Documents
26
Period of Report
2024-05-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 63326
2 ex4-1.htm EX-4.1 129738
3 ex4-2.htm EX-4.2 128490
4 ex4-3.htm EX-4.3 138009
5 ex5-1.htm EX-5.1 22803
6 ex5-2.htm EX-5.2 16876
7 ex10-1.htm EX-10.1 297104
8 ex10-2.htm EX-10.2 83260
9 ex99-1.htm EX-99.1 17857
10 ex5-1_001.jpg GRAPHIC 18693
11 ex5-1_002.jpg GRAPHIC 6410
12 ex5-2_001.jpg GRAPHIC 5580
  Complete submission text file 0001493152-24-020460.txt   1334212

Data Files

Seq Description Document Type Size
13 XBRL SCHEMA FILE bctx-20240514.xsd EX-101.SCH 3750
14 XBRL DEFINITION FILE bctx-20240514_def.xml EX-101.DEF 26591
15 XBRL LABEL FILE bctx-20240514_lab.xml EX-101.LAB 36631
16 XBRL PRESENTATION FILE bctx-20240514_pre.xml EX-101.PRE 25215
30 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5650
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 24960754
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)